Cells expressing recombinant growth factor receptors
AssigneeInstil Bio (UK) Limited
InventorJohn Stephen Bridgeman
Life of this patent
Estimating the term…
Abstract
The present invention discloses cell lines and recombinant growth factor receptors useful in adoptive cell therapy (ACT), wherein the recombinant growth factor receptor can act as a molecular switch enabling cells expressing the rGFR protein to be expanded in-vitro or in- vivo. Thus the invention provides a T or NK cell, comprising a recombinant growth factor receptor (rGFR) comprising: (i) an extracellular (EC) domain; (ii) a thrombopoietin receptor transmembrane (TM) domain; and (iii) a growth factor receptor intracellular (IC) domain.
Claims22
A T or natural killer (NK) cell comprising a recombinant thrombopoietin receptor (TpoR) comprising:
- (i) a thrombopoietin receptor extracellular (EC) domain,
- (ii) a thrombopoietin receptor transmembrane (TM) domain, and
- (iii) an intracellular (IC) domain;
- wherein the IC domain is from a human growth hormone receptor or a human prolactin receptor.
A nucleic acid encoding a recombinant thrombopoietin receptor (TpoR) comprising:
- (i) a thrombopoietin receptor extracellular (EC) domain,
- (ii) a thrombopoietin receptor transmembrane (TM) domain, and
- (iii) an intracellular (IC) domain;
- wherein the IC domain is from a human growth hormone receptor or a human prolactin receptor.
Dependencies are inferred from the claim text.